FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

SYNCOM

0.7
+0.05 (7.69%)
Updated 03:19 09/04 IST

SYNCOM Buy or Sell - FrontPage Forums

1 Users have submitted 2 trade ideas of Rs. 1,050 for SYNCOM
Disclaimer
100% Bullish
0% Bearish

SYNCOM Buy or Sell - Brokerage Reports

No. of reports in last year
0
No. of analysts
0
Average Consensus Forecast
Consensus Potential
0.00%
See SYNCOM Share Price Targets >>

SYNCOM Ratings

Long term SYNCOM rating by FrontPage users
0/5 (0 Ratings)0
Find answers to all your questions on live SYNCOM message board: Is SYNCOM buy or sell? Should I buy SYNCOM shares? Why are SYNCOM shares falling? Should I invest in SYNCOM stock?

  1. Home
  2. SYNCOM Forum

SYNCOM Share Price Discussion

N
Reputation: 4,369 • Jul 23 1:48 AM
Goldman Sachs ups stake in Rossari Biotech, Norges Bank raises holding in IndiaMART
Plutus Wealth Management bought 4,77,637 shares in the company at Rs 669.25 per share.
Moneycontrol
Like
Reply
N
Reputation: 4,369 • Jul 6 2:43 AM
Infinity Holdings acquires stake in Camlin Fine Sciences, Alpha Leon offloads shares in Syncom Health
Alpha Leon Enterprises sold 2,50,013 shares in Syncom Healthcare at Rs 3.33 per share
Moneycontrol
Like
Reply
N
Reputation: 4,369 • Jul 3 2:48 AM
Carlyle Group arm almost exits Metropolis, Alpha Leon sells further stake in McLeod Russel
The investment arm of the Carlyle group raised Rs 84.23 crore via sale of 6,28,123 shares
Moneycontrol
Like
Reply
N
Reputation: 4,369 • Jul 2 2:58 AM
Kotak Mahindra International offloads stake in KRBL, Alpha Leon buys shares in McLeod Russel
As of March-end 2020, Kotak Mahindra (International) held 2.32 percent or 54,64,635 shares in KRBL.
Moneycontrol
Like
Reply
N
Reputation: 4,369 • Jul 1 2:28 AM
HDFC MF acquires shares in Anup Engineering, Birla Sun Life Insurance offloads stake in Somany Ceramics
Birla Sun Life Insurance Company sold 2,27,000 shares in Somany Ceramics (representing 0.53 percent of its total paid-up equity capital) at Rs 117.8 per share
Moneycontrol
Like
Reply
N
Reputation: 4,369 • Jun 26 4:03 AM
KMC Speciality Standalone March 2020 Net Sales at Rs 23.23 crore, up 10.69% Y-o-Y
Moneycontrol
Like
Reply
V
Reputation: -29,478 • Jun 22 6:39 AM

Type
Buy
Instrument
SYNCOM
Entry Price
₹0.7
Price@Trade
₹0.7
Target Price
₹5
Stop Price
₹0.1
Valid Till
Jun 22, 2021 3:20 AM
Margin
₹945 approx for 1350 Qty
Status
Active
Like
Reply
V
Reputation: -29,478 • Jun 22 6:39 AM

Type
Buy
Instrument
SYNCOM
Entry Price
₹0.7
Price@Trade
₹0.7
Target Price
₹5
Stop Price
₹0.1
Valid Till
Jun 22, 2021 3:20 AM
Margin
₹105 approx for 150 Qty
Status
Active
Like
Reply
N
Reputation: 4,369 • May 30, 2019 11:23 AM
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • SYNCOM - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization8.16
    Enterprise Value30.68
    Price to Earnings168.52
    Price to Book Value1.83
    Return on Capital Employed-1.89
    Return on Equity-6.6
    Face Value10
    Dividend YieldNA
  • SYNCOM Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Apr 900.70.70.7
    Apr 800.650.650.65
    Apr 300.550.50.55
    Apr 100.550.50.55
    Mar 3100.550.50.55
  • SYNCOM Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹0.52
    30 Day Moving Average₹0.55
    50 Day Moving Average₹0.63
    100 Day Moving Average₹1.4
    200 Day Moving Average₹2.59
  • SYNCOM - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue4253.22-0.21
    Operating Profit-5-69.56-0.93
    Profit Before Tax-66-75.97-0.13
    Net Income-66-83.88-0.21
  • SYNCOM - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds-0.910-1.09
    Total Liabilities50.3651-0.01
    Total Assets49.4661-0.19
  • SYNCOM - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity613.19-0.55
    Cash from Investing Activity-1-3.85-0.74
    Cash from Financing Activity-5-9.94-0.5
    Net Cash FlowNA-0.6-1
  • SYNCOM - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets-1.08-0.71
    Return on Equity-6.6-1.1
    Return on Capital Employed-1.89-0.71
  • SYNCOM - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue-0.32
    3 Year CAGR Growth in Operating Profit-4.21
    3 Year CAGR Growth in EBIDTA-421.69
    3 Year CAGR Growth in Net Income-16.28
    3 Yr CAGR Growth - Diluted EPS-16.19
  • SYNCOM - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue-0.55
    5 Year CAGR Growth in Operating Profit-2.33
    5 Year CAGR Growth in EBIDTA-12.55
    5 Year CAGR Growth in Net Income-287.96
    3 Yr CAGR Growth - Diluted EPS-276
  • SYNCOM - Recent News

    keyboard_arrow_down
    NewsBot
    Jul 23 1:48 AM
    Goldman Sachs ups stake in Rossari Biotech, Norges Bank raises holding in IndiaMART
    Moneycontrol
    NewsBot
    Jun 26 4:03 AM
    KMC Speciality Standalone March 2020 Net Sales at Rs 23.23 crore, up 10.69% Y-o-Y
    Moneycontrol
    NewsBot
    May 30, 2019 11:23 AM
    NewsBot
    Feb 11, 2019 6:57 AM
    NewsBot
    Nov 9, 2018 8:47 AM
  • SYNCOM - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Apollo Hospitals Enterprise Ltd. NSE:...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020